Raytheon awarded $71 million in Navy contracts for missile systems
Mizuho (NYSE:MFG) Securities USA LLC, a significant stakeholder in Aimei Health Technology Co., Ltd. (NASDAQ:AFJK), has recently sold a substantial portion of its holdings in the company. The stock, currently trading near its 52-week high of $10.87, has shown relatively low price volatility according to InvestingPro analysis. According to a recent SEC filing, Mizuho Securities disposed of 150,000 shares of Aimei Health Technology’s common stock at a price of $10.86 per share. This transaction totals approximately $1.63 million. Following this sale, Mizuho Securities retains ownership of 550,387 shares in the company. With a market capitalization of $97.66 million and a P/E ratio of 36.16, InvestingPro analysis suggests the stock is currently trading slightly above its Fair Value. InvestingPro subscribers have access to 6 additional key insights about AFJK’s financial health and growth prospects.
The sale was executed on February 11, 2025, and was signed off by Gregory Doig. Mizuho Securities, a subsidiary of Mizuho Americas, remains a significant ten percent owner of Aimei Health Technology, which maintains a Fair financial health score according to InvestingPro’s comprehensive evaluation system.
In other recent news, Aimei Health Technology Co., Ltd. has been making significant changes to its financial structure. The company’s shareholders recently approved an amendment to their Investment Management Trust Agreement with Continental Stock Transfer & Trust Company. This change adjusts the amount deposited into the trust account for each monthly extension of the deadline to finalize an initial business combination. The deposit is now a flat rate of $150,000 for all outstanding public shares per extension.
Aimei Health Technology also issued a promissory note for $150,000 to its sponsor, Aimei Investment Ltd, and United Hydrogen Group Inc. This note will fund the extension payment and does not bear interest. The principal is due upon completion of a business combination with United Hydrogen.
However, at a recent extraordinary general meeting, shareholders voted against a proposed amendment to the trust agreement. The proposed amendment sought to change the deposit amount from $0.033 per public share to the lesser of $50,000 for all outstanding public shares or $0.033 for each outstanding public share, for each monthly extension.
These are the latest developments in Aimei Health Technology’s ongoing efforts to finalize its business combination with United Hydrogen.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.